Translate Bio Inc. (TBIO) NASDAQ
$37.36 0 (0.00%)
Market Cap: $0
As of 09/13/21 12:00 AM EDT. Market closed.
Translate Bio Inc. (TBIO) NASDAQ
$37.36 0 (0.00%)
Market Cap: $0
As of 09/13/21 12:00 AM EDT. Market closed.
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an ... read more
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, or to prevent infectious diseases by generating protective immunity. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases with a lead pulmonary candidate being evaluated as an inhaled treatment for cystic fibrosis (CF) in a Phase 1/2 clinical trial. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform. Translate Bio also believes its technology may apply broadly to a wide range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation. Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| BAUPOST GROUP LLC/MA | 10% Owner | Sep 14, 2021 | Option Exercise | $38.00 | 18,044,239 | 685,681,082 | 0 | Sep 16, 2021, 05:43 PM |
| Renaud Ronald C JR | Chief Executive Officer | Sep 14, 2021 | Sale | $38.00 | 409,913 | 15,576,694 | 0 | Sep 14, 2021, 07:32 PM |
| Renaud Ronald C JR | Chief Executive Officer | Sep 14, 2021 | Sale | $38.00 | 503,231 | 19,122,778 | 0 | Sep 14, 2021, 07:32 PM |
| Renaud Ronald C JR | Chief Executive Officer | Sep 14, 2021 | Sale | $38.00 | 40,909 | 1,554,542 | 0 | Sep 14, 2021, 07:32 PM |
| Renaud Ronald C JR | Chief Executive Officer | Apr 07, 2021 | Option Exercise | $7.39 | 9,026 | 66,702 | 503,231 | Sep 14, 2021, 07:31 PM |
| Burgess Paul D. | Chief Operating Officer, CLO | Sep 14, 2021 | Sale | $38.00 | 71,833 | 2,729,654 | 0 | Sep 14, 2021, 07:29 PM |
| Hughes Owen | Director | Sep 14, 2021 | Sale | $38.00 | 29,860 | 1,134,680 | 0 | Sep 14, 2021, 07:26 PM |
| FORMELA JEAN FRANCOIS | Director | Sep 14, 2021 | Sale | $38.00 | 2,055,063 | 78,092,394 | 0 | Sep 14, 2021, 07:23 PM |
| Sanofi | 10% Owner | Sep 14, 2021 | Buy | $38.00 | 71,983,597 | 2,735,376,686 | 75,668,031 | Sep 14, 2021, 09:59 AM |
| Renaud Ronald C JR | Chief Executive Officer, Pres. | Jan 14, 2021 | Option Exercise | $7.39 | 5,639 | 41,673 | 494,205 | Jan 14, 2021, 07:59 PM |
| FORMELA JEAN FRANCOIS | Director | Dec 22, 2020 | Sale | $25.07 | 82,565 | 2,069,870 | 46,640 | Dec 23, 2020, 06:07 PM |
| FORMELA JEAN FRANCOIS | Director | Dec 21, 2020 | Sale | $25.50 | 56,536 | 1,441,928 | 126,505 | Dec 23, 2020, 06:07 PM |
| Renaud Ronald C JR | Chief Executive Officer, Pres. | Nov 16, 2020 | Option Exercise | $7.39 | 53,007 | 391,725 | 488,566 | Nov 18, 2020, 07:30 PM |
| FORMELA JEAN FRANCOIS | Director | Aug 27, 2020 | Sale | $14.38 | 10,097 | 145,217 | 3,833,122 | Aug 27, 2020, 08:14 PM |
| FORMELA JEAN FRANCOIS | Director | Aug 26, 2020 | Sale | $14.80 | 44,381 | 656,746 | 3,843,219 | Aug 27, 2020, 08:14 PM |
| FORMELA JEAN FRANCOIS | Director | Aug 25, 2020 | Sale | $15.00 | 34,410 | 516,160 | 3,887,600 | Aug 27, 2020, 08:14 PM |
| Shire Human Genetic Therapies, Inc. | 10% Owner | Jun 30, 2020 | Sale | $20.68 | 6,824,992 | 141,140,837 | 0 | Jun 30, 2020, 08:24 PM |
| BAUPOST GROUP LLC/MA | 10% Owner | Jun 26, 2020 | Buy | $22.00 | 500,000 | 11,000,000 | 18,044,239 | Jun 30, 2020, 05:37 PM |
| Shire Human Genetic Therapies, Inc. | 10% Owner | Jun 03, 2020 | Sale | $19.75 | 40,086 | 791,699 | 6,824,992 | Jun 05, 2020, 09:52 AM |
| Shire Human Genetic Therapies, Inc. | 10% Owner | Jun 02, 2020 | Sale | $19.76 | 105,395 | 2,082,903 | 6,870,084 | Jun 03, 2020, 06:08 AM |
| Shire Human Genetic Therapies, Inc. | 10% Owner | Jun 01, 2020 | Sale | $19.86 | 108,472 | 2,154,121 | 6,971,873 | Jun 03, 2020, 06:08 AM |
| Gallagher Brian M. Jr. | Director | Jul 02, 2018 | Buy | $13.00 | 269,230 | 3,499,990 | 3,697,912 | Jul 05, 2018, 04:30 PM |
| MRL Ventures Fund LLC | 10% Owner | Jul 02, 2018 | Buy | $13.00 | 25,000 | 325,000 | 1,873,503 | Jul 03, 2018, 06:44 PM |
| GLAXOSMITHKLINE PLC | 10% Owner | Jul 02, 2018 | Buy | $13.00 | 269,230 | 3,499,990 | 3,697,912 | Jul 03, 2018, 05:59 PM |